The Status of Neuroimaging with SPECT and PET in Germany: Results from the 1st Survey on Nuclear Neuroimaging in Germany in 2023
Nuklearmedizin - NuclearMedicine · 01.08.2025 · 64 (04) · 250-261
DOI: 10.1055/a-2566-1487 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nuklearmedizin - NuclearMedicine, erschienen am 01.08.2025. Verfasst von Ralph Buchert und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diagnostic and Interventional Radiology and Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Hauptthemen laut MEDLINE: Tomography, Emission-Computed, Single-Photon, Positron-Emission Tomography, Neuroimaging. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The advent of disease-modifying therapies for neurodegenerative diseases may result in a growing demand for nuclear neuroimaging procedures presenting opportunities but also challenges to the nuclear medicine community. Whether capacity and expertise in Germany are sufficient to meet an increasing demand for nuclear neuroimaging is under discussion. Against this background, the Neuroimaging Working Group of the German Society of Nuclear Medicine initiated the first survey on the status of nuclear neuroimaging in Germany in 2023. 82 institutions participated in the survey: 33 practices, 15 community hospitals, 34 university hospitals. Primary findings were the following. In practices, brain scans are less frequently performed than in hospitals and are often limited to dopamine transporter SPECT. Brain PET is mainly performed in hospitals, and in community hospitals it is often restricted to FDG PET. Nevertheless, availability of amyloid PET with well-certified quality can be taken for granted. Thus, access to amyloid PET will not be a major bottleneck for new treatments of Alzheimer’s disease. Adequate reimbursement and clear anchoring in clinical guidelines have the greatest potential to advance nuclear neuroimaging in Germany. Clinical dopamine transporter SPECT is largely in agreement with procedure guidelines. An area for improvement is the limited availability of MR images to avoid misinterpretation of structural/vascular lesions as nigrostriatal degeneration. The survey provides the first systematic assessment of the status of nuclear neuroimaging in Germany. It underscores the capacity of the German nuclear medicine community to meet an increasing demand for neuroimaging procedures, its adherence to procedure guidelines and identifies topics for improvement.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Diagnostic and Interventional Radiology and Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Institute of Neuroscience and Medicine (INM-2), Forschungszentrum Jülich, Jülich, Germany.
- Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
- German Center for Neurodegenerative Diseases (DZNE), Bonn-Cologne, Germany.
- Department of Nuclear Medicine, Johannes Gutenberg University, Mainz, Germany.
- Institute of Neuroscience and Medicine (INM-3/INM-4/INM-5/INM-11), Forschungszentrum Jülich, Jülich, Germany.
ORCID-Profile: Ralph Buchert
Zitieren
APA
Buchert, R., Drzezga, A., Schreckenberger, M., Langen, K. J., Meyer, P. T., & Working Group Nuclear Neuroimaging of the German Society of Nuclear Medicine (DGN e.V.) (2025). The Status of Neuroimaging with SPECT and PET in Germany: Results from the 1st Survey on Nuclear Neuroimaging in Germany in 2023. Nuklearmedizin - NuclearMedicine, 64(04), 250-261. https://doi.org/10.1055/a-2566-1487
Vancouver
Buchert R, Drzezga A, Schreckenberger M, Langen KJ, Meyer PT, Working Group Nuclear Neuroimaging of the German Society of Nuclear Medicine (DGN e.V.). The Status of Neuroimaging with SPECT and PET in Germany: Results from the 1st Survey on Nuclear Neuroimaging in Germany in 2023. Nuklearmedizin - NuclearMedicine. 2025;64(04):250-261. doi:10.1055/a-2566-1487
BibTeX
@article{Buchert2025,
author = {Buchert, Ralph and Drzezga, Alexander and Schreckenberger, Mathias and Langen, Karl Josef and Meyer, Philipp T and Working Group Nuclear Neuroimaging of the German Society of Nuclear Medicine (DGN e.V.), Working Group Nuclear Neuroimaging of the German Society of Nuclear Medicine (DGN e.V.)},
title = {The Status of Neuroimaging with SPECT and PET in Germany: Results from the 1st Survey on Nuclear Neuroimaging in Germany in 2023},
journal = {Nuklearmedizin - NuclearMedicine},
year = {2025},
volume = {64},
number = {04},
pages = {250--261},
doi = {10.1055/a-2566-1487}
}
EUVIMED